Molecular structure of Raltitrexed, CAS Number: 112887-68-0
Raltitrexed (CAS 112887-68-0)
Application:
Raltitrexed is an inhibitor of thymidylate synthase and DHFR
CAS Number:
112887-68-0
Purity:
≥99%
Molecular Weight:
458.49
Molecular Formula:
C21H22N4O6S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Folate-based inhibitor of thymidylate synthase that is rapidly and extensively metabolized to its more potent polyglutamate derivatives. Antineoplastic.
Raltitrexed (CAS 112887-68-0) References
- The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats. | Jodrell, DI., et al. 1991. Cancer Chemother Pharmacol. 28: 331-8. PMID: 1914075
- An In Vitro Comparative Study of Three Drug-Eluting Beads Loaded with Raltitrexed. | Lu, E., et al. 2023. Cancer Biother Radiopharm. 38: 641-649. PMID: 34767737
- Raltitrexed regulates proliferation and apoptosis of HGC-27 cells by upregulating RSK4. | Hu, C., et al. 2022. BMC Pharmacol Toxicol. 23: 65. PMID: 36031631
- Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis. | Zhen, H., et al. 2023. BMC Cancer. 23: 207. PMID: 36870981
- Identification of a PD1/PD-L1 inhibitor by structure-based pharmacophore modelling, virtual screening, molecular docking and biological evaluation. | Choorakottayil Pushkaran, A., et al. 2023. Mol Inform. 42: e2200254. PMID: 36897739
- Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations. | Gul, F., et al. 2023. PLoS One. 18: e0283743. PMID: 37000796
- Molecular docking analysis of MCL-1 inhibitors for breast cancer management. | Abdulrahman, A., et al. 2023. Bioinformation. 19: 707-712. PMID: 37885779
- Selective reprogramming of regulatory T cells in solid tumors can strongly enhance or inhibit tumor growth. | Alfar, R., et al. 2023. Front Immunol. 14: 1274199. PMID: 37928524
- Repurposing of Raltitrexed as an Effective G9a/EHMT2 Inhibitor and Promising Anti-Alzheimer's Agent. | Jana, A., et al. 2023. ACS Med Chem Lett. 14: 1531-1536. PMID: 37974951
- Raltitrexed induces apoptosis through activating ROS-mediated ER stress by impeding HSPA8 expression in prostate cancer cells. | Tao, Y., et al. 2024. Biochim Biophys Acta Mol Cell Res. 1871: 119684. PMID: 38301906
- Redirecting raltitrexed from cancer cell thymidylate synthase to Mycobacterium tuberculosis phosphopantetheinyl transferase. | Singh, A., et al. 2024. Sci Adv. 10: eadj6406. PMID: 38489355
- Effect of Raltitrexed on ECA109 Cellular Radiosensitivity and Its Mechanism in Esophageal Cancer. | Xu, LB., et al. 2024. Curr Pharm Des.. PMID: 38716546
- ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. | Jackman, AL., et al. 1995. Eur J Cancer. 31A: 1277-82. PMID: 7577036
Inhibitor of:
γ-FR, AdSS1, ALDH1L2, C20orf54, cSHMT, DHFR, DHFRL1, Enzyme, Folate, Folic Acid, FRP-1, HCP1 (SLC46A1), MFT, mSHMT, MTHFD2L, MTHFS, MTHFSD, PCBD2, Su, THTPA, TMSL3, TRMU, and TS.Activator of:
α-FR, AICAR transformylase, DHFR, DTYMK, and RFC-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Raltitrexed, 10 mg | sc-219933 | 10 mg | $143.00 |